Literature DB >> 15584494

Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients.

Richard A Smith1, James E Berg, Laura E Pope, Janice D Callahan, Daniel Wynn, Ronald A Thisted.   

Abstract

Pseudobulbar affect (PBA) or pathological laughing and crying (PLC) is a disorder of affect that occurs in about 10% of multiple sclerosis (MS) patients. The objective of this study was to validate the CNS Emotional Lability Scale (CNS-LS) in MS patients and to correlate the results with the frequency and intensity of episodes of PLC. Physicians at seven private practice referral centers in the United States made a diagnosis concerning PLC based on patient interviews. Clinical coordinators separately administered the CNS-LS, a self-report measure of PLC with seven questions, to MS patients, including patients known to exhibit PLC, patients thought to be free of PLC, and newly diagnosed patients where PLC status was unknown, and the physician was blinded as to the results. A receiver operating characteristic (ROC) curve analysis was performed to define a cut-off best correlating with the physician's diagnosis. Of 90 MS patients selected to complete the survey, 50 were physician diagnosed with PLC; 40 were without PLC, and 15 of these 90 patients were newly diagnosed with MS (<6 months). Scores of 17 or higher corresponded to a sensitivity of 0.94 and a specificity of 0.83 (LR+ = 5.5, LR- = 0.07); 89% of patients were correctly diagnosed. The area under the ROC curve was 0.95. Symptoms were greater in patients diagnosed as PLC than in non-PLC patients as evidenced by mean number of episodes/week, number of days/week with episodes, duration of an episode and total time in an episode. Similar results were observed if patients were classified as PLC or non-PLC according to CNS-LS score > or = 17, suggesting that the CNS-LS is a valid measure for the assessment of PLC in MS patients and could be a useful instrument for clinical and research purposes.

Entities:  

Mesh:

Year:  2004        PMID: 15584494     DOI: 10.1191/1352458504ms1106oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  17 in total

1.  Behaviour, physiology and experience of pathological laughing and crying in amyotrophic lateral sclerosis.

Authors:  Nicholas T Olney; Madeleine S Goodkind; Catherine Lomen-Hoerth; Patrick K Whalen; Craig A Williamson; Deborah E Holley; Alice Verstaen; Laurel M Brown; Bruce L Miller; John Kornak; Robert W Levenson; Howard J Rosen
Journal:  Brain       Date:  2011-12-06       Impact factor: 13.501

2.  Pseudobulbar affect: prevalence and quality of life impact in movement disorders.

Authors:  Roy E Strowd; Michael S Cartwright; Michael S Okun; Ihtsham Haq; Mustafa S Siddiqui
Journal:  J Neurol       Date:  2010-04-08       Impact factor: 4.849

Review 3.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Involuntary emotional expression disorder (IEED) in Parkinson's disease.

Authors:  Lisa Phuong; Shalini Garg; John E Duda; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2009-01-31       Impact factor: 4.891

5.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014

6.  Posterior Fossa Lesion Load and Pathological Laughing and Crying in Multiple Sclerosis.

Authors:  Jacqueline A Luhoway; Manas Sharma; Suresh Menon; Heather Rosehart; Sarah A Morrow
Journal:  Int J MS Care       Date:  2019 May-Jun

7.  Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Authors:  Kathryn C Fitzgerald; Amber Salter; Tuula Tyry; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2018-12

8.  PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Authors:  Benjamin Rix Brooks; David Crumpacker; Jonathan Fellus; Daniel Kantor; Randall E Kaye
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 9.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

Review 10.  Pseudobulbar affect: prevalence and management.

Authors:  Aiesha Ahmed; Zachary Simmons
Journal:  Ther Clin Risk Manag       Date:  2013-11-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.